FierceBiotechOriginal article
{"a":[{"_":"Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail","$":{"href":"/biotech/sionna-lays-46-workforce-strategic-shift-after-cystic-fibrosis-trial-fail","hreflang":"en"}}]}
Data ReadoutnegativeNegative
AI Analysis
Summary
Sionna Therapeutics is laying off 46% of its workforce following the failure of its cystic fibrosis add-on therapy trial. The company is undergoing a strategic restructuring in response to the clinical setback.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Cystic fibrosis add-on program trial failed
Importance:6/10
Sentiment:
-0.85
layoffcystic fibrosistrial failurerestructuring
Read the original article
Published by FierceBiotech on September 15, 2026 7:21 AM